European guidelines on perioperative venous thromboembolism prophylaxis: Patients with preexisting coagulation disorders and after severe perioperative bleeding

被引:16
作者
Ahmed, Aamer [1 ]
Kozek-Langenecker, Sibylle [2 ,3 ]
Mullier, Francois [4 ]
Pavord, Sue [5 ]
Hermans, Cedric [6 ,7 ]
机构
[1] Univ Hosp Leicester NHS Trust, Glenfield Hosp, Dept Anaesthesia, Groby Rd, Leicester LE3 9QP, Leics, England
[2] Sigmund Freud Private Univ, Vienna, Austria
[3] Evangel Hosp Vienna, Dept Anaesthesia & Intens Care, Vienna, Austria
[4] Catholic Univ Louvain, CHU UCLNamur, Namur Thrombosis & Hemostasis Ctr, Namur, Belgium
[5] Oxford Univ Hosp, Dept Clin Haematol, Oxford, England
[6] St Luc Univ Hosp, Div Haematol, Haemostasis & Thrombosis Unit, Brussels, Belgium
[7] St Luc Univ Hosp, Haemophilia Ctr, Brussels, Belgium
关键词
MOLECULAR-WEIGHT HEPARIN; VON-WILLEBRAND DISEASE; FACTOR-XA INHIBITOR; GLOMERULAR-FILTRATION-RATE; RESTARTING ORAL ANTICOAGULANTS; HEPATIC VENOOCCLUSIVE DISEASE; TOTAL KNEE ARTHROPLASTY; WARFARIN TREATMENT INR; TOTAL HIP-ARTHROPLASTY; INJURY REMAIN COMPLEX;
D O I
10.1097/EJA.0000000000000725
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
In patients with inherited bleeding disorders undergoing surgery, we recommend assessment of individual risk for venous thromboembolism, taking into account the nature of the surgery and anaesthetic, type and severity of bleeding disorder, age, BMI, history of thrombosis, the presence of malignancy and other high-risk comorbidities. Venous thromboembolism risk should be balanced against the increased bleeding risk associated with anticoagulant use in patients with known bleeding disorders (Grade 1C). In these patients undergoing major surgery, we recommend against routine postoperative use of pharmacological thromboprophylaxis, especially for patients with haemophilia A and B (Grade 1B). Glomerular filtration rate should be assessed before initiation of each direct oral anticoagulant, and also at least once a year or more frequently as needed, such as postoperatively before the resumption of therapeutic direct oral anticoagulant administration, when it is suspected that renal function could decline or deteriorate (Grade 1C). Reduced dosages of low molecular weight heparins may be used relatively safely during transient severe (<50x10(9)l(-1)) thrombocytopaenia (Grade 2C). Monitoring of anti-Xa levels may be used to adjust the doses of low molecular weight heparin in patients with moderate or severe thrombocytopaenia (Grade 2C). The delay between major gastrointestinal bleeding and resuming warfarin should be at least 7 days (Grade 2C). For patients at a high risk of thromboembolism and with a high bleeding risk after surgery, we consider that administering a reduced dose of direct oral anticoagulant on the evening after surgery and on the following day (first postoperative day) after surgery is a good practice (Grade 2B).
引用
收藏
页码:96 / 107
页数:12
相关论文
共 176 条
[81]   Timing of the resumption of antithrombotic agents following surgical evacuation of chronic subdural hematomas: a retrospective cohort study [J].
Guha, Daipayan ;
Coyne, Shona ;
Macdonald, R. Loch .
JOURNAL OF NEUROSURGERY, 2016, 124 (03) :750-759
[82]   Is laboratory monitoring of low-molecular-weight heparin therapy necessary? Yes [J].
Harenberg, J .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (04) :547-550
[83]   Management of anticoagulation following central nervous system hemorrhage in patients with high thromboembolic risk [J].
Hawryluk, G. W. J. ;
Austin, J. W. ;
Furlan, J. C. ;
Lee, J. B. ;
O'Kelly, C. ;
Fehlings, M. G. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (07) :1500-1508
[84]   Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation [J].
Heidbuchel, Hein ;
Verhamme, Peter ;
Alings, Marco ;
Antz, Matthias ;
Diener, Hans-Christoph ;
Hacke, Werner ;
Oldgren, Jonas ;
Sinnaeve, Peter ;
Camm, A. John ;
Kirchhof, Paulus .
EUROPACE, 2015, 17 (10) :1467-1507
[85]   Renal function estimations and dose recommendations for dabigatran, gabapentin and valaciclovir: a data simulation study focused on the elderly [J].
Hellden, Anders ;
Odar-Cederlof, Ingegerd ;
Nilsson, Goran ;
Sjoviker, Susanne ;
Soderstrom, Anders ;
von Euler, Mia ;
Ohlen, Gunnar ;
Bergman, Ulf .
BMJ OPEN, 2013, 3 (04)
[86]   Enoxaparin can be used safely in patients with severe thrombocytopenia due to intensive chemotherapy regimens [J].
Herishanu, Y ;
Misgav, M ;
Kirgner, I ;
Ben-Tal, O ;
Eldor, A ;
Naparstek, E .
LEUKEMIA & LYMPHOMA, 2004, 45 (07) :1407-1411
[87]  
Hermanides J, 2009, NETH J MED, V67, P226
[88]   Subclinical deep venous thrombosis observed in 10% of hemophilic patients undergoing major orthopedic surgery [J].
Hermans, C. ;
Hammer, F. ;
Lobet, S. ;
Lambert, C. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (05) :1138-1140
[89]   Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis [J].
Hijazi, Ziad ;
Hohnloser, Stefan H. ;
Oldgren, Jonas ;
Andersson, Ulrika ;
Connolly, Stuart J. ;
Eikelboom, John W. ;
Ezekowitz, Michael D. ;
Reilly, Paul A. ;
Siegbahn, Agneta ;
Yusuf, Salim ;
Wallentin, Lars .
CIRCULATION, 2014, 129 (09) :961-970
[90]   Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients -: A double-blind, randomized comparison [J].
Hull, RD ;
Pineo, GF ;
Francis, C ;
Bergqvist, D ;
Fellenius, C ;
Soderberg, K ;
Holmqvist, A ;
Mant, M ;
Dear, R ;
Baylis, B ;
Mah, A ;
Brant, R .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (14) :2199-2207